FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine for Adults 50+
TL;DR Summary
The FDA reversed its earlier decision and will review Moderna’s new mRNA flu vaccine for adults 50 and older, using a standard pathway for ages 50–64 and accelerated approval for those 65+, with a required post‑marketing study and a target review date of August 5.
- FDA reverses course, agrees to review Moderna’s flu vaccine statnews.com
- FDA reverses course and will review Moderna’s mRNA flu shot, company says CNN
- F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times The New York Times
- FDA reverses course, will review Moderna flu shot after controversial refusal The Boston Globe
- U.S. rejection of new mRNA flu vaccine 'sends chills,' epidemiologist says PBS
Reading Insights
Total Reads
1
Unique Readers
9
Time Saved
2 min
vs 3 min read
Condensed
89%
422 → 45 words
Want the full story? Read the original article
Read on statnews.com